( SAN DIEGO--(BUSINESS WIRE)--Jun 6 2007...)Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with,Electroporation DNA Delivery Technology and New Devices at Gene,Therapy Meeting,Health

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today the company delivered multiple presentations on preclinical study results and new device innovations relating to its electroporation-mediated DNA delivery technology at the 10th Annual Meeting of the American Society of Gene Therapy (ASGT). Inovio's DNA delivery systems are designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.

Three presentations reported preclinical data regarding immune responses to DNA vaccines directed against major infectious diseases including malaria, HIV, and hepatitis C, respectively. In all cases, Inovio's electroporation technology was well tolerated and significantly enhanced both humoral (antibody) and cellular (T-cell) immune responses when compared with traditional vaccine delivery methods.

A study conducted in collaboration with the Naval Medical Research Center showed that electroporation-augmented immunization with a DNA vaccine against a malaria parasite-specific antigen not only enhanced humoral and cellular immune responses, but more importantly caused a significant reduction of parasite burden compared to non-immunized control animals.

A study conducted in partnership with Wyeth tested a multi-antigenic DNA vaccine against HIV. Using only one-fifth the dose used without electroporation, antibody responses were increased several hundred-fold by electroporation. The cellular immune response was enhanced 10 to 40-fold, translating into a 50 to 200-fold increase (8 weeks and 22 weeks, respectively) in vaccine potency.

A third study conducted in partnership with the Karolinska Institute, Sweden, supported the safety of electroporation in detailed experiments a
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia